Article Details

IL-2 without the toxic side effects? Orbimed backs the idea in Synthorx' $63M round

Retrieved on: 2018-04-29 20:00:00

Tags for this article:

Click the tags to see associated articles and topics

IL-2 without the toxic side effects? Orbimed backs the idea in Synthorx' $63M round. View article details on hiswai:

Excerpt

<div>The company, incubated in its early days at <b>Avalon Ventures</b>' startup campus COI Pharmaceuticals, attracted A-list talent late last year when Laura Shawver came on board as CEO. Shawver is best known for leading Cleave Biosciences through two sizable rounds of funding. She left Cleave when it was ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up